since constriction of arterio-venous shunts was not inhibited , ergotamine is unlikely to lose its effectiveness in migraine patients under concomitant dihydropyridine treatment , while unwanted vasoconstrictor effects are likely to be diminished .
C0014710
ergotamine
C0149931
migraine